导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.36% | 1663/4773 |
| 近一周 | -1.70% | 660/5462 |
| 近一月 | -3.88% | 2044/5421 |
| 近一季 | -5.00% | 1745/5209 |
| 近半年 | -1.60% | 1648/4920 |
| 近一年 | 4.92% | 1653/4366 |
| 近两年 | 58.73% | 1248/2954 |
| 近三年 | 31.11% | 1011/2253 |
| 成立以来 | 28.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.98% 2598/4961 |
18.22% 1405/5312 |
- - |
- - |
| 2025 | 26.83% 1601/4813 |
0.68% 1792/3635 |
2.39% 1597/4076 |
26.19% 1357/4524 |
-2.50% 3161/4813 |
| 2024 | 8.83% 1512/3463 |
-1.59% 1244/2808 |
-3.33% 1351/3014 |
16.66% 1390/3129 |
-1.94% 1894/3463 |
| 2023 | -8.83% 1065/2656 |
7.41% 580/2280 |
-4.81% 1293/2385 |
-3.46% 935/2515 |
-7.63% 2181/2655 |
| 2022 | -23.94% 1177/2207 |
-15.84% 1077/1919 |
3.13% 1211/2016 |
-14.66% 1128/2113 |
2.70% 860/2208 |
| 2021 | 0.86% 702/1822 |
-2.96% 732/1255 |
9.26% 571/1330 |
-5.51% 815/1466 |
0.67% 1080/1822 |
| 2020 | 22.03% 679/1250 |
-9.64% 701/1028 |
14.40% 553/1067 |
7.48% 778/1164 |
9.83% 622/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.09% 751/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证长三角ETF联接C VS. 长安沪深300非周期A(740101) |